Drugs / UX053
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT04990388 | Oct 2021 → Mar 2023 | glycogen storage disease III | Ultragenyx Pharmaceutical Inc | Terminated | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | UX053 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04990388 ↗ |
| Route | Intravenous | “peripheral intravenous (IV) infusion of UX053” NCT04990388 ↗ |